当前位置: X-MOL 学术J. Exp. Clin. Cancer Res. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Retraction Note: Receptor tyrosine kinase inhibitor Sunitinib and integrin antagonist peptide HM-3 show similar lipid raft dependent biphasic regulation of tumor angiogenesis and metastasis
Journal of Experimental & Clinical Cancer Research ( IF 11.4 ) Pub Date : 2020-02-17 , DOI: 10.1186/s13046-020-1538-8
Jialiang Hu , Wenjing Wang , Chen Liu , Mengwei Li , Edouard Nice , Hanmei Xu

The authors have retracted this article [1] because the bands shown in Fig. 5 panel D for GTP-RhoA/Control, GTP-RhoA/Sunitinib (2 and 64 nM) and GTP-RhoA/HM-3 (4.5 and 72 uM) are not data generated as part of this study. All authors agree to this retraction.

中文翻译:

撤回说明:受体酪氨酸激酶抑制剂舒尼替尼和整联蛋白拮抗剂肽HM-3显示相似的脂质筏依赖性肿瘤血管生成和转移的双相调节。

作者撤回了本文[1],因为图5图D所示的GTP-RhoA /对照,GTP-RhoA /舒尼替尼(2和64 nM)和GTP-RhoA / HM-3(4.5和72 uM)的条带)不是本研究中生成的数据。所有作者都同意这种撤回。
更新日期:2020-04-22
down
wechat
bug